JP2017510297A - 核酸分子ワクチン組成物およびその使用 - Google Patents

核酸分子ワクチン組成物およびその使用 Download PDF

Info

Publication number
JP2017510297A
JP2017510297A JP2017501087A JP2017501087A JP2017510297A JP 2017510297 A JP2017510297 A JP 2017510297A JP 2017501087 A JP2017501087 A JP 2017501087A JP 2017501087 A JP2017501087 A JP 2017501087A JP 2017510297 A JP2017510297 A JP 2017510297A
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
antigen
peptide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017501087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510297A5 (https=
Inventor
ロバート ゼット． フロキーヴィッチ，
ロバート ゼット． フロキーヴィッチ，
Original Assignee
タピミューン インコーポレイテッド
タピミューン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タピミューン インコーポレイテッド, タピミューン インコーポレイテッド filed Critical タピミューン インコーポレイテッド
Publication of JP2017510297A publication Critical patent/JP2017510297A/ja
Publication of JP2017510297A5 publication Critical patent/JP2017510297A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/50—Vectors comprising a special translation-regulating system utilisation of non-ATG initiation codon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017501087A 2014-03-17 2015-03-17 核酸分子ワクチン組成物およびその使用 Pending JP2017510297A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461954588P 2014-03-17 2014-03-17
US61/954,588 2014-03-17
PCT/US2015/021117 WO2015142963A1 (en) 2014-03-17 2015-03-17 Nucleic acid molecule vaccine compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019168454A Division JP2019205482A (ja) 2014-03-17 2019-09-17 核酸分子ワクチン組成物およびその使用

Publications (2)

Publication Number Publication Date
JP2017510297A true JP2017510297A (ja) 2017-04-13
JP2017510297A5 JP2017510297A5 (https=) 2018-04-26

Family

ID=52774612

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017501087A Pending JP2017510297A (ja) 2014-03-17 2015-03-17 核酸分子ワクチン組成物およびその使用
JP2019168454A Pending JP2019205482A (ja) 2014-03-17 2019-09-17 核酸分子ワクチン組成物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019168454A Pending JP2019205482A (ja) 2014-03-17 2019-09-17 核酸分子ワクチン組成物およびその使用

Country Status (8)

Country Link
US (8) US9364523B2 (https=)
EP (1) EP3119893A1 (https=)
JP (2) JP2017510297A (https=)
CN (1) CN106459992A (https=)
AU (2) AU2015231461B2 (https=)
BR (1) BR112016021345A8 (https=)
CA (1) CA2942501A1 (https=)
WO (1) WO2015142963A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019069561A1 (ja) * 2017-10-03 2019-04-11 公益財団法人東京都医学総合研究所 インフルエンザに対する医薬
JP2021506861A (ja) * 2017-12-19 2021-02-22 アコーオス インコーポレイテッド 内耳への治療用抗体のａａｖ媒介送達
US12365726B2 (en) 2020-12-01 2025-07-22 Akouos, Inc. Anti-VEGF antibody constructs

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016184822A1 (en) 2015-05-15 2016-11-24 Curevac Ag Prime-boost regimens involving administration of at least one mrna construct
SMT202200370T1 (it) 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
EP3452082A1 (en) 2016-05-04 2019-03-13 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
US10835596B2 (en) 2016-07-15 2020-11-17 Etubics Corporation Compositions and methods for flavivirus vaccination
JP6903120B2 (ja) * 2016-07-15 2021-07-14 エトゥビクス コーポレーション アルファウイルスワクチン接種のための組成物及び方法
CA3044424C (en) * 2016-11-21 2023-05-23 Nant Holdings Ip, Llc Fractal combination therapy
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
CN110117675B (zh) * 2018-02-05 2022-03-04 西比曼生物科技（香港）有限公司 一种实时荧光定量pcr检测rcl的试剂和方法
CN108619499A (zh) * 2018-04-17 2018-10-09 南昌大学 一种结核病疫苗及其制备工艺
CN110144334B (zh) * 2019-05-05 2021-03-16 中国水产科学研究院长江水产研究所 一种共表达草鱼呼肠孤病毒外衣壳蛋白vp4和vp35的重组杆状病毒的制备方法和应用
IL293012A (en) * 2019-11-20 2022-07-01 Bavarian Nordic As Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva
BR112022015565A2 (pt) * 2020-02-07 2022-09-27 Modernatx Inc Vacinas de domínio de mrna para sars-cov-2
CN111330002B (zh) * 2020-03-09 2020-12-01 北京鼎成肽源生物技术有限公司 靶向冠状病毒的通用dc细胞疫苗及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US6028058A (en) * 1997-07-21 2000-02-22 Ciblex Corporation Methods and compositions for regulating nuclear trafficking of proteins
US6709863B2 (en) 1999-12-08 2004-03-23 Iowa State University Research Foundation Nucleic acid molecules encoding multiple start codons and histidine tags
US20110111413A1 (en) 2001-02-02 2011-05-12 Padgett Hal S Method of optimizing codon usage through dna shuffling
CA2500955A1 (en) 2002-10-03 2004-04-15 Genencor International, Inc. Optimized multi-epitope constructs and uses thereof
CA2685300C (en) 2006-06-01 2017-01-03 Mayo Foundation For Medical Education And Research Immunity to folate receptors
CA2673757A1 (en) 2006-11-30 2008-06-05 Tapimmune Inc. Poxviridae treatment
US20080292918A1 (en) 2007-05-25 2008-11-27 Caine Finnerty Electrochemical system having multiple independent circuits
JP2011502484A (ja) 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
US8858952B2 (en) * 2009-02-19 2014-10-14 Mayo Foundation For Medical Education And Research Methods and materials for generating T cells
EP2545071A2 (en) 2010-03-09 2013-01-16 Maksyutov, Amir Polyepitope constructs and methods for their preparation and use
WO2015063647A1 (en) 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AYYAVOO V; ET AL: "IMMUNOGENICITY OF A NOVEL DNA VACCINE CASSETTE EXPRESSING MULTIPLE HUMAN 以下備考", AIDS, vol. VOL:14, NR:1, JPN5017002206, 7 January 2000 (2000-01-07), GB, pages 1 - 09, ISSN: 0003996703 *
BONNAL SOPHIE; ET AL: "A SINGLE INTERNAL RIBOSOME ENTRY SITE CONTAINING A G QUARTET RNA STRUCTURE 以下備考", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. VOL:278, NR:41, JPN5017002203, 10 October 2003 (2003-10-10), US, pages 39330 - 39336, ISSN: 0003996700 *
DOUIN VICTORINE; BORNES STEPHANIE; CREANCIER LAURENT; ET AL: "USE AND COMPARISON OF DIFFERENT INTERNAL RIBOSOMAL ENTRY SITES (IRES) 以下備考", BMC BIOTECHNOLOGY, vol. VOL:4, NR:1, JPN5017002204, 27 July 2004 (2004-07-27), GB, pages 1 - 12, ISSN: 0003996701 *
F-A MIR; KAUFMANN S H E; EDDINE A N: "A MULTICISTRONIC DNA VACCINE INDUCES SIGNIFICANT PROTECTION AGAINST TUBERCULOSIS IN 以下備考", CLINICAL AND VACCINE IMMUNOLOGY, vol. VOL:16, NR:10, JPN5017002205, 1 October 2009 (2009-10-01), pages 1467 - 1475, ISSN: 0003996702 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019069561A1 (ja) * 2017-10-03 2019-04-11 公益財団法人東京都医学総合研究所 インフルエンザに対する医薬
CN111065400A (zh) * 2017-10-03 2020-04-24 公益财团法人东京都医学总合研究所 抗流感药物
JPWO2019069561A1 (ja) * 2017-10-03 2020-10-22 公益財団法人東京都医学総合研究所 インフルエンザに対する医薬
JP2021506861A (ja) * 2017-12-19 2021-02-22 アコーオス インコーポレイテッド 内耳への治療用抗体のａａｖ媒介送達
JP2024016118A (ja) * 2017-12-19 2024-02-06 アコーオス インコーポレイテッド 内耳への治療用抗体のａａｖ媒介送達
US12275960B2 (en) 2017-12-19 2025-04-15 Akouos, Inc. AAV-mediated delivery of therapeutic antibodies to the inner ear
US12365726B2 (en) 2020-12-01 2025-07-22 Akouos, Inc. Anti-VEGF antibody constructs

Also Published As

Publication number Publication date
US20160354455A1 (en) 2016-12-08
CA2942501A1 (en) 2015-09-24
AU2021282438A1 (en) 2021-12-23
JP2019205482A (ja) 2019-12-05
US20160367652A1 (en) 2016-12-22
US20220033844A1 (en) 2022-02-03
US20180163226A1 (en) 2018-06-14
CN106459992A (zh) 2017-02-22
EP3119893A1 (en) 2017-01-25
US10030252B2 (en) 2018-07-24
BR112016021345A2 (https=) 2017-10-03
US20220056473A1 (en) 2022-02-24
US9655956B2 (en) 2017-05-23
AU2015231461A1 (en) 2016-10-06
AU2015231461B2 (en) 2021-09-09
US20170016026A1 (en) 2017-01-19
US9364523B2 (en) 2016-06-14
BR112016021345A8 (pt) 2022-07-05
US9988643B2 (en) 2018-06-05
US20150258186A1 (en) 2015-09-17
WO2015142963A1 (en) 2015-09-24
US20180230487A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
JP2019205482A (ja) 核酸分子ワクチン組成物およびその使用
JP7629178B2 (ja) 同種異系腫瘍細胞ワクチン
AU2006293659C1 (en) Chemo-immunotherapy method
AU2017211387A1 (en) Personalized delivery vector-based immunotherapy and uses thereof
JP7712919B2 (ja) マルチドメインタンパク質ワクチン
CN112930394B (zh) 表达ii类主要组织相容性复合物的癌细胞疫苗和用于产生整合免疫应答的使用方法
WO2021074655A1 (en) Cancer vaccine
Odegard et al. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy
JP2025041678A (ja) 新規な癌抗原及び方法
KR20220029560A (ko) 신규한 암 항원 및 방법
KR20210041593A (ko) 암의 예방 또는 치료의 방법에 사용하기 위한 암/고환 항원을 암호화하는 바이러스 벡터
CA3142329A1 (en) Novel cancer antigens and methods
WO2020260897A1 (en) Novel cancer antigens and methods
KR20220034039A (ko) 신규한 암 항원 및 방법
CA3179694A1 (en) Fusion proteins of ctl antigens for treating melanoma
TW201730342A (zh) 多基因組反轉錄病毒載體製劑及產生及使用其之方法及系統
EP4136096A1 (en) Antigen pool

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201023